Patents Assigned to Santaris Pharma A/S
-
Patent number: 7846911Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIP-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: October 15, 2009Date of Patent: December 7, 2010Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Publication number: 20100292311Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: April 22, 2010Publication date: November 18, 2010Applicants: Enzon Pharmaceuticals, Santaris Pharma A/SInventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20100280099Abstract: The present invention relate to the use of a combination of an inhibitor of miR-122 and an inhibitor of VLDL assembly, for the treatment of HCV, hyperlipidemia and hypercholesterolemia.Type: ApplicationFiled: October 3, 2008Publication date: November 4, 2010Applicant: Santaris Pharma A/SInventor: Joacim Elmèn
-
Publication number: 20100234451Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.Type: ApplicationFiled: March 18, 2010Publication date: September 16, 2010Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/SInventor: Jesper WORM
-
Publication number: 20100227914Abstract: Short oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with Apo-B100 expression are provided. The oligonucleotides comprise deoxyribonucleosides and locked nucleic acids.Type: ApplicationFiled: March 19, 2008Publication date: September 9, 2010Applicant: Santaris Pharma A/SInventors: Henrik Frydenlund Hansen, Jens Bo Rode Hansen, Christoph Rosenbohm, Ellen Marie Straarup
-
Patent number: 7785834Abstract: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.Type: GrantFiled: May 1, 2007Date of Patent: August 31, 2010Assignees: Ercole Biotech, Inc., University of North Carolina at Chapel Hill, Santaris Pharma A/SInventors: Peter L. Sazani, Maria Graziewicz, Ryszard Kole, Henrik Ørum
-
Publication number: 20100210712Abstract: The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.Type: ApplicationFiled: March 19, 2008Publication date: August 19, 2010Applicant: Santaris Pharma A/SInventors: Jens Bo Rode Hansen, Henrik Frydenlund Hansen, Ellen Marie Straarup, Niels Fisker Nielsen, Maj Hedtjarn
-
Patent number: 7741309Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: GrantFiled: June 29, 2009Date of Patent: June 22, 2010Assignees: Santaris Pharma A/SInventors: Jens Bo Rode Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Patent number: 7737264Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: April 4, 2003Date of Patent: June 15, 2010Assignees: Santaris Pharma A/SInventors: Charlotte Albæk Thrue, Anja Mølhart Høg, Paul E. G. Kristjansen
-
Patent number: 7737125Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.Type: GrantFiled: November 26, 2008Date of Patent: June 15, 2010Assignees: Enzon Pharamaceuticals, Inc., Santaris Pharma, A/SInventor: Jesper Worm
-
Patent number: 7713738Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: GrantFiled: February 10, 2004Date of Patent: May 11, 2010Assignees: Santaris Pharma A/SInventors: Bo Hansen, Charlotte Albæk Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20100093839Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIP-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: October 15, 2009Publication date: April 15, 2010Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E.G. Kristjansen
-
Patent number: 7687617Abstract: The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy.Type: GrantFiled: November 18, 2003Date of Patent: March 30, 2010Assignee: Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Christoph Rosenbohm, Henrik Frydenlund Hansen, Majken Westergaard, Nikolaj Dam Mikkelsen, Signe M. Christensen, Troels Koch, Daniel Sejer Pedersen, Miriam Frieden
-
Publication number: 20100062994Abstract: The present application discloses locked nucleoside compounds of the Formula I which act as antagonists of adenosine receptors, in particular the adenosine A3 receptor, and the use of such adenosine A3 receptor compounds in medicine, e.g.Type: ApplicationFiled: July 6, 2007Publication date: March 11, 2010Applicant: SANTARIS PHARMA A/SInventors: Jacob Ravn, Christoph Rosenbohm, Katrine Qvortrup, Troels Koch
-
Publication number: 20100004320Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.Type: ApplicationFiled: March 30, 2007Publication date: January 7, 2010Applicant: Santaris Pharma A/SInventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen
-
Publication number: 20090298916Abstract: The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.Type: ApplicationFiled: March 9, 2009Publication date: December 3, 2009Applicant: Santaris Pharma A/SInventors: Sakari Kauppinen, Niels Abrahamsen, Elisabeth Hildebrandt-Eriksen, Martin Munk
-
Patent number: 7622453Abstract: The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position No. 1459 (5?) to No. 1476 (3?) of the human Bcl-2 mRNA, said target binding domain having the formula: 5?-[(DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3? and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (—O—P(O,S)—O—). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.Type: GrantFiled: December 23, 2004Date of Patent: November 24, 2009Assignee: Santaris Pharma A/SInventors: Miriam Frieden, Jens B. Hansen, Henrik Orum, Majken Westergaard, Charlotte A. Thrue
-
Publication number: 20090286859Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.Type: ApplicationFiled: June 3, 2009Publication date: November 19, 2009Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Majken Westergaard, Charlotte A. Thrue, Frank W. Rasmussen, Henrik F. Hansen
-
Patent number: 7589190Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.Type: GrantFiled: November 9, 2005Date of Patent: September 15, 2009Assignees: Santaris Pharma A/SInventors: Majken Westergaard, Charlotte A. Thrue, Frank W. Rasmussen, Henrik F. Hansen
-
Publication number: 20090203137Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.Type: ApplicationFiled: January 21, 2009Publication date: August 13, 2009Applicant: Santaris Pharma A/SInventor: Jesper Worm